This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or polypropylene | Low-binding options reduce peptide adsorption |
| Typical shipping condition | Dry ice or gel packs | Choice depends on required temperature range |
| Light protection | Amber vial or foil wrap | Reduces photodegradation of sensitive residues |
| Reconstitution solvent | Water, buffer, or organic co-solvent | Depends on peptide solubility and assay requirements |
| Temperature monitoring | Data logger or indicator | Documents excursions during transport and storage |
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
=== Hollow fiber flow === Hollow fiber flow FFF (HF5) was developed by Lee et al. (1974). HF5 has been applied towards the analysis of proteins and other macromolecules. HF5 was the first form of flow FFF to be developed in 1974. The advantage is that HF5 offers a disposable channel unit which can be readily replaced in routine applications. One of the drawbacks of HF5 is the limited choice of membrane materials; only polyether sulfone (PES) membranes are available. Currently, HF5 is not widely used, because of the lack of flexibility and limitations in sample load.
== Clinical significance == There is a rare pathology known as edema of Wharton’s jelly. Its causes have not been established. In some cases, the development of edema is associated with fetal hydrops. In addition, edema may occur in cases of umbilical cord hemangiomas. In such cases, the risk of compression of the umbilical cord vessels increases, which may lead to impaired blood supply to the fetus. Wharton’s jelly edema is usually detected in the second half of pregnancy. The edema may involve the entire umbilical cord or only certain segments of it. In addition to edema, pathologies of Wharton’s jelly include mucoid degeneration accompanied by the formation of pseudocysts, as well as underdevelopment and constriction (coarctation) of the umbilical cord. A 2015 study showed that transplantation of Wharton’s jelly tissue may be considered as a strategy for the treatment of traumatic brain injury.
Muscular dystrophy is a group of disorders associated with progressive muscle weakness and loss of muscle mass. These disorders are caused by genetic mutations. The disease affects between 19.8 and 25.1 per 100,000 person-years globally. There are more than 30 types of muscular dystrophy. Depending on the type, muscular dystrophy can affect a person's heart and lungs, and can affect the ability to move, walk, and perform daily activities. The most common types include:
The level measurement of liquids in pressure vessels and tanks in the petrochemical industry is undertaken by differential pressure level meters, radar, magnetostrictive, nucleonic, magnetic float and pneumatic bubbler instruments.
Mikania micrantha is a widespread weed in the tropics. It grows very quickly (as fast as 80 to 90 millimetres (3.1 to 3.5 in) in 24 hours for a young plant) and covers other plants, shrubs and even trees. Mikania is a problem in Nepal, covering more than 20% of the Chitwan National Park. Various control measures against Mikania have been tried in many countries. It is moderately susceptible to the herbicides 2,4-D and 2,4,5-T and paraquat. Cuscuta, a parasitic plant, has been used in Assam and Sri Lanka to suppress the spread of Mikania from waste land to tea plantations. Other control measures include the rust fungus Puccinia spegazzinii and the thrips species Liothrips mikaniae. An example of its success can be seen in Hong Kong where first recorded in 1884, it has now spread throughout the region and invades its country parks. Economic gains due to Mikania are meager compared to the loss due to its infestation in various ecosystems. It is used as a fodder in many countries. Sheep preferentially grazed Mikania in Malaysia and other cattle also relish it. In Kerala, India, the weed is utilized as a fodder in some parts of the state, especially during summer when the availability of grass is scarce. However, Mikania is known to cause hepatotoxicity and liver damage in dairy cattle. The antibacterial effect of Mikania and its efficacy in wound healing has been reported. In Assam (NE India), Kabi tribes use the leaf juice of Mikania as an antidote for insect bite and scorpion sting. The leaves are also used for treating stomachache.
Sources: en.wikipedia.org
=== Development of databases === HMRBase: A manually curated database of hormones and their receptors. It is a compilation of sequence data after extensive manual literature search and from publicly available databases. HMRBase can be searched on the basis of a variety of data types. Owing to the high impact of endocrine research in the biomedical sciences, HMRBase could become a leading data portal for researchers. The salient features of HMRBase are hormone-receptor pair-related information, mapping of peptide stretches on the protein sequences of hormones and receptors, Pfam domain annotations, categorical browsing options, and online data submission. This database is integrated with DrugPedia so the public can contribute. BIAdb: A database for Benzylisoquinoline Alkaloids. The Benzylisoquinoline Alkaloid Database serves to gather information related to the BIA's. Many BIA's show therapeutic properties and can be considered as potent drug candidates. This database will also serve researchers working in the field of synthetic biology, as developing medicinally important alkaloids using synthetic process is one of the important challenges. This database is also integrated with DrugPedia so the public can contribute. Antigen DB: This database contain more than 500 antigens collected from literature and other immunological resources. These antigens come from 44 pathogenic species. In Antigen DB, a database entry contains information regarding the sequence, structure, origin, etc.
This drastically revamped King Crimson had no plans to record in the studio, focusing instead on playing "reconfigured" versions of past material live. According to Levin, the band "were instructed/advised by Robert Fripp to look at the older classic King Crimson material as if we had written it. And so we did that with a lot of older material that the band had done before the '80s. We didn't actually cover that much of the '80s material outside of a few songs." For the most part, this approach would remain consistent for the remainder of the band's lifetime. In early 2014, the band's repertoire included songs from the run of albums between In the Court of the Crimson King and Larks' Tongues in Aspic for the first time since 1974, as well as reviving song material from Red. No songs with vocals by Belew were included in the setlist, although some instrumentals from his tenure were played. Some material from A Scarcity of Miracles was also incorporated into the band's repertoire. After rehearsing in England, King Crimson toured North America from 9 September to 6 October. Recordings from the Los Angeles dates were released as Live at the Orpheum; this included the newly-written instrumentals "Banshee Legs Bell Hassle" and "Walk On: Monk Morph Chamber Music". Tours of Europe, Canada, and Japan followed in the later half of 2015. Brand-new songs mainly written by Fripp and Jakszyk were debuted at the concerts, as well as drum showcases.
In road transport, the Emission Performance Regulation 2019 says manufacturers of "new passenger cars" should not allow emissions to exceed 95 grams of CO2 per kilometre, and 147 grams of CO2 per kilometre for new light commercial vehicles, but this is merely an "EU fleet-wide target" rather than requirements for each vehicle. Manufacturers can agree to pool their production quotas, so as to meet their targets on average, but there is no legal sanction for failure to meet the target. Member states are simply required to record the relevant success or failure, and manufacturers' performance is published. By contrast the Vehicles Emissions Regulation 2007 sets the "Euro 6" standards in maximum emissions that car manufacturers can have. Since the 'Euro 1' standard was introduced in 1992, standards became cleaner each 4 to 5 years, but recently stalled. Article 2 states this applies to vehicles under 2,610 kilograms, while the Heavy Vehicle Emission Regulation 2019 applies to heavier vehicles, with looser CO2 limits. Article 4 states manufacturers must 'demonstrate that all new vehicles sold, registered or put into service in the Community are type approved in accordance with this Regulation'. Article 6 requires manufacturers to 'provide unrestricted and standardised access to vehicle repair and maintenance information' should there be any non-compliance. Article 13 requires penalties imposed by member states for breach are 'effective, proportionate and dissuasive', and breaches include any 'false declarations' as well as 'use of defeat devices'.
== Treatment == Multiple effective therapies are available for the treatment of DM. Standard treatment typically consists of a combination of glucocorticoids and steroid-sparing immunosuppressive agents, including methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, and cyclosporine. Intravenous immunoglobulin (IVIG) has demonstrated efficacy in DM. Although rituximab did not meet its primary endpoint in randomized clinical trials, it remains an important treatment option in clinical practice, particularly for refractory disease, often in combination with IVIG. Janus kinase (JAK) inhibitors, including tofacitinib, ruxolitinib, baricitinib, and brepocitinib, have shown efficacy in dermatomyositis. Additional strategies targeting the type I interferon pathway have also demonstrated benefit, including blockade of interferon-β with dazukibart. Brepocitinib (Lisraya) was approved for medical use in the United States in August 2026. Deep B-cell depletion with CD19 chimeric antigen receptor (CAR) T-cell therapy has shown preliminary evidence of inducing sustained, and potentially treatment-free, remission in DM. Similarly, plasma cell–targeted therapies, including CAR T-cell approaches and monoclonal antibodies, as well as inhibitors of the neonatal Fc receptor (FcRn), such as efgartigimod, have emerged as promising therapeutic strategies for DM. Antimalarial medications, such as hydroxychloroquine, have historically been used to manage the cutaneous manifestations of DM.
atmosphere (atm) manometric units: centimetre, inch, millimetre (torr) and micrometre (mTorr, micron) of mercury, height of equivalent column of water, including millimetre (mm H2O), centimetre (cm H2O), metre, inch (in. WC), and foot of water; imperial and customary units: kip, short ton-force, long ton-force, pound-force, ounce-force, and poundal per square inch, short ton-force and long ton-force per square inch, fsw (feet sea water) used in underwater diving, particularly in connection with diving pressure exposure and decompression; non-SI metric units: bar, decibar, millibar, msw (metres sea water), used in underwater diving, particularly in connection with diving pressure exposure and decompression, kilogram-force, or kilopond, per square centimetre (technical atmosphere), gram-force and tonne-force (metric ton-force) per square centimetre, barye (dyne per square centimetre), kilogram-force and tonne-force per square metre, sthene per square metre (pieze).
Sources: en.wikipedia.org
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.
Aliquots limit repeated thawing and refreezing and repeated vial opening, both of which can promote degradation. They also reduce the chance of contaminating an entire batch. Single-use portions should be labeled with identity, concentration, solvent, and date.
Inspect the package for damage and confirm that temperature indicators or data loggers stayed within the specified range. Check the vial condition and labeling before placing it into storage. Record any excursion or discrepancy for the supplier or quality system.
No. Allowing the sealed vial to equilibrate to room temperature reduces condensation on the powder. Condensation can introduce moisture and promote degradation. Equilibration usually takes 15 to 30 minutes depending on vial size.